Related Experiment Video
Updated: May 19, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Intralesional bevacizumab use for invasive ocular surface squamous neoplasia
1Department of Ophthalmology, Dean A. McGee Eye Institute, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma 73104, USA.
Purpose:
Report the use of bevacizumab intralesional injection as an adjunctive therapy in a patient with ocular surface squamous neoplasia (OSSN) after an incomplete response to topical and intralesional chemotherapy.
Methods:
This is a case report of a 79-year-old man who was treated with topical and intralesional chemotherapy (interferon-alpha-2b, mitomycin-C, and 5-fluorouracil) over 22 months with incomplete resolution of severe OSSN. Intralesional bevacizumab was tried as an adjuvant treatment to resolve the residual tumor.
Results:
Grossly and histologically there was no significant change in the residual tumor after treatment with intralesional bevacizumab.
Conclusions:
While intralesional bevacizumab has been utilized as a treatment modality in the use of other squamous tumors, further studies on the use of bevacizumab in squamous neoplasia would be needed to recommend this treatment for the ocular surface. In the absence of further studies, the current topical and intralesional chemotherapeutic agents should continue to be the mainstay of medical treatment for squamous neoplasia; surgical management is still the definitive treatment.
More Related Videos
06:15Anterior High-Resolution Optical Coherence Tomography in the Diagnosis and Therapeutic Monitoring of Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019